Real-world efficacy and safety of TS-1 plus endocrine therapy in hormone receptor-positive, HER2-negative early-stage breast cancer: A multicenter Taiwanese experience including NATALEE-eligible population.

Authors / 作者群

Ching-Ting Wei ¹ ; Li-Kun Ko ² ; Yen-Dun Tzeng ³

Affiliation / 服務單位

1.Division of General Surgery, Department of Surgery, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan

2.Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan

3.Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan

Audio / 音訊檔

Category / 主題分類

Clinical Research

Keyword / 關鍵字

Breast Cancer; HR-positive/HER2-negative; TS-1; Adjuvant Therapy; NATALEE criteria; Real-World Evidence

Back to list